Ubiquitin-modifying enzymes in thyroid cancer：Mechanisms and functions
Xingmin Xiong,
BenBen Huang,
Zhe Gan,
Weixiang Liu,
Yang Xie,
Jianing Zhong,
Xiangtai Zeng
Affiliations
Xingmin Xiong
Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China; Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, 323 National Road, Ganzhou, 341000, Jiangxi, China
BenBen Huang
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, 323 National Road, Ganzhou, 341000, Jiangxi, China
Zhe Gan
Ganzhou Key Laboratory of Thyroid Cancer, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China
Weixiang Liu
Institute of Thyroid and Parathyroid Disease, Gannan Medical University, Ganzhou, Jiangxi, 341000, China
Yang Xie
Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China; Ganzhou Key Laboratory of Thyroid Cancer, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China
Jianing Zhong
Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, 323 National Road, Ganzhou, 341000, Jiangxi, China; Corresponding author.
Xiangtai Zeng
Department of Thyroid and Hernia Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, 341000, China; Institute of Thyroid and Parathyroid Disease, Gannan Medical University, Ganzhou, Jiangxi, 341000, China; Corresponding author. First Affiliated Hospital of Gannan Medical University, No. 128 Jinlingxi Road, Huangjin Economic & Technological Development District, Ganzhou, 341000, Jiangxi, China.
Thyroid cancer is the most common malignant tumor of the endocrine system, and evidence suggests that post-translational modifications (PTMs) and epigenetic alterations play an important role in its development. Recently, there has been increasing evidence linking dysregulation of ubiquitinating enzymes and deubiquitinases with thyroid cancer. This review aims to summarize our current understanding of the role of ubiquitination-modifying enzymes in thyroid cancer, including their regulation of oncogenic pathways and oncogenic proteins. The role of ubiquitination-modifying enzymes in thyroid cancer development and progression requires further study, which will provide new insights into thyroid cancer prevention, treatment and the development of novel agents.
